Objective：To investigate the association between the X-ray repair cross complementing（XRCC） group 5, XRCC6 and XRCC7 polymorphisms and risk of acute myeloid leukemia（AML）. Methods：This hospital-based case-contro...Objective：To investigate the association between the X-ray repair cross complementing（XRCC） group 5, XRCC6 and XRCC7 polymorphisms and risk of acute myeloid leukemia（AML）. Methods：This hospital-based case-control study included 120 AML patients and 210 cancer-free controls in a Chinese population. Three polymorphisms of XRCC5, XRCC6 and XRCC7 were genotyped using the polymerase chain reaction（PCR） or polymerase chain reaction-restriction fragment length polymorphism（PCR-RFLP） method. Results： We found that there was a significant decrease in risk of AML associated with the XRCC6 -61 CG/GG genotype（adjusted odd ratio （OR） = 0.55; 95% confident interval（CI） = 0.34-0.89） compared with the -61CC genotype. For the novel tandem repeat polymorphism （VNTR） in the XRCC5 promoter, we found when the XRCC5 six genotypes were dichotomized（i.e., 2R/2R, 2R/1R versus 2R/0R, 1R/1R, 1R/0R and 0R/0R）, the latter group was associated with increased risk of AML（adjusted OR = 1.67; 95% CI = 1.00-2.79） compared to 2R/ 2R＋2R/1R genotype. However, the XRCC7 6721G〉T polymorphism had no effect on risk of AML. Conclusion：The XRCC6 -61C 〉 G and XRCC5 2R/1R/0R polymorphisms, but not XRCC7 6721G 〉 T polymorphism, could play an important role in the development of AML. Larger scale studies with more detailed data on environment exposure are needed to verify these findings.展开更多
基金supported in part by National Natural Science Foundation of China(30571541)Natural Science Foundation of Jiangsu Province(BK2006233,BK2005161)+1 种基金Medicine Foundation of Jiangsu Province(H200506)Creative Science Foundation of Nanjing Medical University(CX2004002)
文摘Objective：To investigate the association between the X-ray repair cross complementing（XRCC） group 5, XRCC6 and XRCC7 polymorphisms and risk of acute myeloid leukemia（AML）. Methods：This hospital-based case-control study included 120 AML patients and 210 cancer-free controls in a Chinese population. Three polymorphisms of XRCC5, XRCC6 and XRCC7 were genotyped using the polymerase chain reaction（PCR） or polymerase chain reaction-restriction fragment length polymorphism（PCR-RFLP） method. Results： We found that there was a significant decrease in risk of AML associated with the XRCC6 -61 CG/GG genotype（adjusted odd ratio （OR） = 0.55; 95% confident interval（CI） = 0.34-0.89） compared with the -61CC genotype. For the novel tandem repeat polymorphism （VNTR） in the XRCC5 promoter, we found when the XRCC5 six genotypes were dichotomized（i.e., 2R/2R, 2R/1R versus 2R/0R, 1R/1R, 1R/0R and 0R/0R）, the latter group was associated with increased risk of AML（adjusted OR = 1.67; 95% CI = 1.00-2.79） compared to 2R/ 2R＋2R/1R genotype. However, the XRCC7 6721G〉T polymorphism had no effect on risk of AML. Conclusion：The XRCC6 -61C 〉 G and XRCC5 2R/1R/0R polymorphisms, but not XRCC7 6721G 〉 T polymorphism, could play an important role in the development of AML. Larger scale studies with more detailed data on environment exposure are needed to verify these findings.
